2021 Advanced Cytopathology Education: Personalized for Your Future
JOIN US FOR A DYNAMIC EDUCATIONAL COURSE DESIGNED TO HELP ENHANCE YOUR KNOWLEDGE AND SKILLS IN ADVANCED CYTOPATHOLOGY PRACTICE
ACE, at its core, is structured to bring advanced cytopathology topics to regional areas based on current and emerging needs.
As a cytotechnologist, you could be left behind if you don’t develop new skills to keep up with the growing demands of your field. This is the very reason we developed the Advanced Cytopathology Education Program (ACE).
ACE is a two-day education program created to assist you in transitioning into other practice areas by refining, expanding and strengthening your skills. This is the most proactive way for you to navigate your journey through your changing profession so that you remain in demand and an integral part of the laboratory team.
ACE will cover the current and future Cytopathology changes and developments with:
- Highly comprehensive and customized education sessions to enhance diagnostic techniques
- Engaging and interactive educational strategies
- A dynamic, world-renowned faculty
- Fellow cytotechnologists sharing professional growth experiences
Primary audience: cytotechnologists, cytotechnology students, cytopathologists, pathology residents and cytopathology fellows
- Update skills in diagnostic cytopathology to refine the professional practices of both pathologists and cytotechnologists.
- Learn the latest standards in cytology practice including updated terminology and recent advances in technology.
- Recognize the opportunities and roles of the cytopathology laboratory in the era of personalized medicine.
THURSDAY, MAY 13, 2021
*all times are listed as Eastern Time
1:00 pm - 2:00 pm Rapid On-site Evaluation (ROSE) and Triage of Fine Needle Aspiration Specimens: Empowering Emerging Role for Cytotechnologist
Momin T. Siddiqui MD FIAC, Weill Cornell Medicine, New York, New York
Rapid On-site Evaluation (ROSE) is now done routinely on fine needle aspiration cytology being performed by an interventional radiologist, gastroenterologist or pulmonologist. In light of this the cytotechnologists and cytopathologists have to be readily available for being available for the procedure and ROSE. The process can be very helpful for providing patients with an optimal sample for a diagnosis as well as collecting tissue for ancillary testing and prognostic markers. This requires training in the process and to be cognizant of challenges that the cytotechnologists and cytopathologists will encounter. This course will focus on broader aspects of ROSE, its incorporation in cytopathology practices and triaging key specimen types encountered on the FNA service.
2:00 pm-3:00 pm Diagnosing Malignancy by Liver FNA
Martha B. Pitman, MD, Massachusetts General Hospital, Boston, Massachusetts
This lecture delves into morphological features of primary and metastatic malignancies seen on FNA cytology and reviews the immunohistochemical stains that support specific diagnoses.
3:00 pm-3:30 pm Break
3:30 pm -4:30 pm Diagnostic Challenges in Everyday Head and Neck Cytopatholog
Zubair W. Baloch, MD, PhD, University of Pennsylvania Health System, Philadelphia, Pennsylvania
This presentation will focus on diagnostic challenges encountered due to the overlapping morphologic features between normal/reactive, benign and malignant head and neck lesions and how a correct diagnosis can be achieved by employing a multimodal approach of integrating clinical and radiologic data and appropriate use of special studies (immunohistochemistry and molecular studies).
Friday, May 14, 2021
*all times are listed as Eastern Time
1:00 pm -2:00 pm Cytology Histology Correlation for Cervical Neoplasia
Daniel F.I. Kurtycz, MD, University of Wisconsin, Madison, Wisconsin
This session will offer a discussion on the practice, parameters and issues surrounding Cytology-Histology correlation for the uterine cervix. How accurate is histology and how much trust should be placed in the surgical pathologic interpretation of various forms of cervical and glandular neoplasia? Comparisons of diagnostic systems will be offered including: descriptive, CIN and LAST (Lower Anogenital Squamous Terminology Project). The presentation will be richly illustrated with detailed cytologic and histologic micrographs. Controversies regarding histologic decision points will be reviewed. The role of p16 and other potential biomarkers to help distinguish between diagnostic entities with be examined.
2:00 pm -3:15 pm Where do you see yourself in Five Years?
Setting Goals Throughout Your Career Path (LIVE SESSION)
Kristen A. Atkins, MD, University of Virginia Health System, Charlottesville, Virginia
Michele A. Smith, MS, SCT(ASCP), University of Wisconsin, Madison, Wisconsin
Goals and plans change as you do, not just professionally, but also personally. Many leaders are asked what they might tell their younger selves to make life easier. Their answers? Take chances; do things; understand it is OK to fail. This interaction session will allow participants, at all level, to explore personal or group goal setting in the laboratory and make the pitch to maintain or gain talent. Areas explored will include: competency assessment, quality management, and preparing for the future.
3:15 pm -3:30 pm Break
3:30 pm -4:00 pm CPRC Update: The Move to Master’s
Amber D. Donnelly, PhD, MPH, SCT(ASCP), University of Nebraska Medical Center, Omaha, Nebraska
Recommended updates to the CAAHEP Standards and Guidelines, including entry-level competencies, will be outlined as well as the process for approval and a timeline of events. The challenges and opportunities of how these changes might impact curriculum development, curriculum delivery, student recruitment and resources will be presented.
4:00 pm -5:00 pm Extracting Our Ge'know'mic Advantage; Integrating Cytotechnologists into the Oncology Genome
Melissa L. Randolph, BS, SCT(ASCP), Indiana University Health, Indianapolis, Indiana
The purpose of this course will be to introduce participants into the foundations and pain points of developing the practical knowledge, and competency as pathologist extenders as it relates to tissue selection. The session will be interactive and challenge participants to choose from various types of tissue the most adequate for various clinical scenarios including, IHC, single molecular assays as well as whole genome sequencing. Thresholds and pre-analytic processes will be discussed as a method of creating a process that will allow laboratories to better serve patients and a role that will elevate and challenge cytotechnologists in the era of personalized medicine.
There will be a live ACE Question and Answer Networking event on Thursday, June 3, 2021 at 1:00 PM, EDT to answer any questions about the presentations or the future of cytotechnology.
ACCREDITATION AND DESIGNATION STATEMENTS
Continuing Medical Education (CME)
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this live educational activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 6.75 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 6.75 continuing education credits in the State of Florida and 6.75 in the State of California. The credit on each link is good for three years from the live presentation date.
Current ACCME guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect the speaker’s presentation(s). Therefore, it is the policy of the American Society of Cytopathology to insure balance, independence, objectivity, and scientific rigor in all its educational programs. All planning individuals participating in any ASC Educational Activity are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listener may form his own judgment about the presentation with the full disclosure of the facts. It remains for the audience to determine whether the speaker’s outside interests may reflect a possible bias in either the exposition or the conclusions presented.
All participants involved in developing this educational activity, including Workgroup Facilitators, Executive Board Members, ASC National Office Staff and scheduled speakers have been asked to identify potential conflicts.
Kristen A. Atkins, MD
Zubair Baloch, MD, PhD
|Amber D. Donnelly, PhD, MPH, SCT(ASCP)|
Daniel F.I. Kurtycz, MD
|Martha B. Pitman, MD|
Melissa L. Randolph, BS, SCT(ASCP)
|Momin T. Siddiqui, MD, FIAC|
Michele Smith MS SCT(ASCP)
- 6.75 AMA PRA Category 1 Credit™
- 6.75 California Credits
- 6.75 CMLE
- 6.75 Florida Credits
- 6.75 Participant